“503A” and “503B” refer to sections of federal drug law that draw a line between two different models of pharmaceutical compounding. A 503A facility is typically a traditional compounding pharmacy that prepares customized medications for individual patients, generally tied to a specific prescription. A 503B facility, often called an outsourcing facility, compounds in larger batches, can produce medications without a patient-specific prescription in hand, and operates under a different, more manufacturing-like set of federal quality expectations.
The distinction matters because the two models are regulated differently. 503A compounding is primarily overseen at the state level through the pharmacy’s home board, while 503B facilities register with the federal government and are subject to additional federal oversight on top of applicable state requirements. This affects everything from labeling to how much product a facility can prepare in advance.
Why it matters
Pharmacists working in compounding need to know which category their facility falls into, since it shapes recordkeeping, allowable batch sizes, and how prescriptions must be handled before a preparation can be dispensed. Hospitals and clinics that buy compounded products from outside vendors also care about this distinction, since sourcing from a 503A versus a 503B facility carries different compliance implications. The category a facility operates under also influences which USP compounding standards and beyond-use-date practices come into play.
RxByState tracks how compounding oversight and licensing requirements differ across states. Learn more at https://app.rxbystate.com/signup.